Trial Profile
A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-Ev
- Sponsors United Therapeutics Corporation
- 06 Dec 2023 Results of three additional years of open-label observation after the close of the placebo-controlled, event-driven study, associated with improved survival in FREEDOM-EV and its Open-Label Extension published in the Advances in Therapy
- 24 May 2023 Results performing time to first adjudicated clinical worsening (CW) event using Win Ratio Analysis , presented at the 119th International Conference of the American Thoracic Society
- 19 Oct 2022 Results assessing efficacy of treprostinil in pulmonary arterial hypertension participants in Freedom-Ev (NCT01560624) and the Freedom-Ev Open-Label Extension (OLE, NCT01560637) studies, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.